June 28, 2015 | Hadasit Bio-Holdings announced a letter of intent to raise $2 million from a Chinese business group. Hadasit invests in R&D companies in the medical and bio-technology fields that are in clinical or advanced stages of moving toward clinical trials. The interested Chinese business group specializes on the health sector, namely the pharmaceutical industry. Hadasit Bio-Holdings is the technological transfer company of the Hadassah Medical Center in Jerusalem.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments